FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Together, our findings demonstrate that FLT3 can be used as a prognostic marker and therapeutic target in BP progression and propose that targeting FLT3 and downstream effectors are viable treatment strategies for preventing and overcoming TKI resistance in advanced phase CML.